Laboratory Quality Control and Result Standardization for HLA-B27 Detection Kits: Challenges and Countermeasures

Why HLA-B27 Testing Standardization Is Difficult

The HLA-B27 gene is highly polymorphic, and more than 150 allelic variants have been identified to date, of which only some (such as B*27:02, B*27:04, and B*27:05) are clearly associated with spondyloarthritis, with significant differences in predominant subtypes among different geographic populations. If an HLA-B27 detection kit relies only on a single monoclonal antibody, it may miss certain subtypes or produce cross-fluorescence with HLA-B7, B37, and others. In addition, flow cytometry results are susceptible to interference from red blood cells and dead cell debris, while although PCR kits provide accurate genotyping, their operational workflow is complex, and the equivalence of results between the two has not yet been fully unified. Therefore, the test results of the same patient in different laboratories may be inconsistent, causing difficulties for clinical management.

Quality Control Strategies to Improve Interlaboratory Comparability

To reduce variation in HLA-B27 detection kits, laboratories should implement the following measures: First, establish a stable internal quality control system—in addition to commercial quality control materials, it is recommended to retain previously confirmed weak positive and negative samples as long-term monitoring materials and include them in each batch of testing. Second, select kits registered with the National Medical Products Administration (NMPA) that include validation data for multiple subtypes, and give priority to antibody combinations (such as simultaneous detection of B27 and β2-microglobulin) to distinguish true positives from false positives. For cutoff values (such as an MFI ratio between 1.5 and 2.5), a gray zone should be established and clearly indicated in the report, with PCR recommended for confirmation.

Content and Standardization Recommendations for Result Reporting

A complete HLA-B27 detection kit result report should include, in addition to the qualitative result (positive/negative/weak positive), the following elements: detection method (flow cytometry/PCR), kit lot number and expiration date used, basis for setting the positive threshold, and sample quality assessment (such as cell viability %). If flow cytometry is used, it is recommended to also provide the mean fluorescence intensity (MFI) ratio or a β2-microglobulin co-expression plot. If genotyping is involved, the specific allele name should be listed (such as B*27:05). The report conclusion should avoid absolute statements such as "HLA-B27 positive means a diagnosis of ankylosing spondylitis" and instead use neutral wording such as "HLA-B27 positive test result, please correlate with clinical findings."

Promotion of Standardization by Emerging Technologies

In recent years, kits based on multiplex PCR and next-generation sequencing have gradually entered the market. They can simultaneously capture information on HLA-B27 and associated subtypes and provide more detailed haplotype background, helping to reduce cross-reactivity in flow cytometry methods. However, such kits are relatively costly and place demands on laboratories' bioinformatics analysis capabilities. At the same time, the promotion and application of national reference materials is also accelerating. For example, the National Institutes for Food and Drug Control of China has launched national reference materials for HLA-B27 detection, which laboratories can use for methodological comparison. In the future, with further unification of gating strategies and data analysis software, the standardization of HLA-B27 detection kits is expected to reach a new level.

In summary, reliable results from HLA-B27 detection kits depend on method selection, sustained quality control, and standardized reporting, and close communication between laboratories and clinical departments is key to avoiding misjudgment.